Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis.
about
Novel Therapies for Eosinophilic DisordersPrenatal environmental exposures, epigenetics, and diseaseSerum mucosa-associated epithelial chemokine in atopic dermatitis: a specific marker for severityFood allergen sensitization pattern in adults in relation to severity of atopic dermatitis.Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology.Therapeutic strategies in extrinsic atopic dermatitis: focus on inhibition of IL-4 as a new pharmacological approach.Phenotype of atopic dermatitis subjects with a history of eczema herpeticum.Specific immunotherapy in atopic dermatitis.Effects of Ixeris dentata water extract and caffeic acid on allergic inflammation in vivo and in vitro.Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8Phenotypic characterization of leukocytes in prenatal human dermis.T-helper type 2 polarization among asthmatics during and following pregnancy.The Correlation of Serums CCL11, CCL17, CCL26, and CCL27 and Disease Severity in Patients with Urticaria.Anti-Inflammatory Effect of Quercetagetin, an Active Component of Immature Citrus unshiu, in HaCaT Human Keratinocytes.Immunological mechanisms behind the cystic fibrosis-ABPA link.The imbalance in serum concentration of Th-1- and Th-2-derived chemokines as one of the factors involved in pathogenesis of atopic dermatitis.The Inhibitory Effect of Premature Citrus unshiu Extract on Atopic Dermatitis In Vitro and In Vivo.T cell homing to epithelial barriers in allergic diseaseComparing high altitude treatment with current best care in Dutch children with moderate to severe atopic dermatitis (and asthma): study protocol for a pragmatic randomized controlled trial (DAVOS trial).CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.Mechanisms of leukocyte trafficking in allergic diseases: insights into new therapies targeting chemokines and chemokine receptors.Evaluation of the child with atopic dermatitis.The human cutaneous chemokine system.CCR10 and its ligands in regulation of epithelial immunity and diseases.Which biomarkers are effective for identifying Th2-driven inflammation in asthma?Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis.Targeting key proximal drivers of type 2 inflammation in disease.Qualitative vs. quantitative atopic dermatitis criteria - in historical and present perspectives.Drug evaluation review: dupilumab in atopic dermatitis.The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies.The current and future role of biomarkers in type 2 cytokine-mediated asthma management.A review of the roles of keratinocyte-derived cytokines and chemokines in the pathogenesis of atopic dermatitis in humans and dogs.Serum biomarkers for allergy in children.Chemokines in onchocerciasis patients after a single dose of ivermectin.Atopic dermatitis-mitigating effects of new Lactobacillus strain, Lactobacillus sakei probio 65 isolated from Kimchi.Commonality of the IL-4/IL-13 pathway in atopic diseases.Targeting CD1c-expressing classical dendritic cells to prevent thymus and activation-regulated chemokine (TARC)-mediated T-cell chemotaxis in rheumatoid arthritis.Identification of a distal tandem STAT6 element within the CCL17 locus.Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling.Serum TARC and CTACK concentrations in children with atopic dermatitis, allergic asthma, and urticaria.
P2860
Q26799600-1BBF0CA2-8E1C-478D-85F7-B7CF0FD44B2AQ28391853-9D760A88-8F4A-4182-A97F-F2AADB0AAEF4Q33607633-2EC0071E-497A-4892-AC79-51B52F9B677BQ33617064-173FBEB7-1AB2-47C1-84CC-1012DA7034ADQ34006054-104CAB93-0F5B-4660-8C21-D0C9C42ADEC5Q34441795-AE319288-65A3-4622-8A6F-3B2B6D77BE0DQ34663953-7FA72340-EA3C-4D9B-BCDA-D4364B0D7333Q35420502-DD653AA5-5FD7-4018-B86F-AEED097767E3Q35672240-3904A0B4-F071-4ECD-929D-C25C58E67BDAQ36139731-742DF55A-CBDD-43F0-A9FE-59186E843A6CQ36321219-F2C4BBF9-53A2-45A9-A630-D3A45D39D39DQ36404784-254F22AB-DD60-46BC-9D62-A82C29350A36Q36533483-804578AF-44A0-45DE-B5E1-556913C5F454Q37145579-ADDFA26A-505F-4B58-9792-629B0B45A157Q37225474-D1582BA8-B84F-450A-8BAD-F8FC3CC060D5Q37275230-CFFA6D6C-1201-4B9A-8BA4-39CB3964D87AQ37326256-7EC4278E-ACBB-44B6-A36C-8E21838EBEDBQ37392523-D3905275-E058-4EFB-8AF2-E0EBF72FF685Q37683800-3418CB04-E4E5-4810-9507-71C9394818BCQ37694678-883C0699-68F7-42B3-89B0-20A373CB6760Q37755318-89FFEE20-39B2-4EE1-87C7-3BE3A9CEC47FQ37957299-124A55EB-42EF-4990-82E4-2ACCE0FC0C70Q38008335-CD63E329-CC29-4821-A6D6-082A173C5283Q38017619-A09D9FEA-16D0-4042-83D3-68E4CD415C76Q38126882-A5E2C45C-45CE-46E7-BE94-5E1B48A47C1FQ38195864-47B51C3A-20B8-4127-91E6-CBEE8A4F0057Q38608260-A3A57AFD-62AF-4281-A46B-797CADE36E4EQ38625616-E319A4A8-246E-4D58-9A70-CA4DE6AB5BAFQ38645192-8172BDFC-830B-402E-8379-8F45DF302C72Q38733182-4CA98021-026C-4548-A9EA-9A0CBF54C16DQ38764451-CBE153DD-6A44-428B-946A-C5E7C623A48BQ38899826-E8C7837C-E6B1-4F7B-983D-1BBC4272208CQ38945312-1A3AA387-9688-487F-8F79-BD7F61C339AFQ39001906-70A0A66F-8FCB-4EC6-AB54-0FC27D0380EDQ39162477-6FA0F7E0-8798-4A6F-89D2-1F7D6E9140CAQ39170851-45454089-6854-459E-95B1-978416E1308EQ39717753-365128BC-1A96-496B-AA50-EDF67AE9A706Q41353059-7A453E4F-3301-4BC2-B2C6-6ACF86C13A6EQ43183078-8BF93F0D-58B2-4674-9EEE-562255555D16Q43447241-C29A03C9-C759-4D60-A889-6E7E166F275A
P2860
Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Serum thymus and activation-re ...... markers for atopic dermatitis.
@en
type
label
Serum thymus and activation-re ...... markers for atopic dermatitis.
@en
prefLabel
Serum thymus and activation-re ...... markers for atopic dermatitis.
@en
P2093
P1476
Serum thymus and activation-re ...... markers for atopic dermatitis
@en
P2093
Bert Oosting
Carla Bruijnzeel-Koomen
Cristina Lebre
Esther De Jong
Marjolein De Bruin-Weller
P304
P356
10.1016/J.JACI.2003.12.007
P407
P577
2004-02-01T00:00:00Z